Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (NASDAQ: ATHA), which has announced a transition to the name LeonaBio, Inc. with a new ticker "LONA," regularly issues news updates as a clinical-stage biopharmaceutical company headquartered in the Seattle, Washington area. Its press releases focus on the development of novel small molecule therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).
News for ATHA commonly covers progress in the company’s lead programs, lasofoxifene and ATH-1105. Updates include clinical trial milestones such as completion of a first-in-human Phase 1 trial of ATH-1105 in healthy volunteers, presentations of safety, tolerability and pharmacokinetic data, and enrollment status for the Phase 3 ELAINE-3 trial of lasofoxifene in ER+, HER2-negative, ESR1-mutated metastatic breast cancer. The company also reports on preclinical findings for ATH-1105 in ALS models and scientific presentations at major neurology and ALS-focused conferences.
Investors following ATHA news will also see corporate and regulatory developments, including announcements about a 10-for-1 reverse stock split aimed at maintaining Nasdaq listing requirements, notices of regained compliance with the minimum bid price rule, and details of private placement financings intended to support clinical and regulatory milestones. Additional releases describe Athira’s strategic alternatives review and its licensing agreements with Sermonix Pharmaceuticals and Ligand Pharmaceuticals for lasofoxifene.
This news feed provides a centralized view of Athira/LeonaBio’s clinical, scientific and corporate disclosures, allowing readers to track how its oncology and neurology pipelines evolve over time and how financing and licensing arrangements relate to ongoing and planned trials.
Athira Pharma (NASDAQ: ATHA) will present a corporate overview at the H.C. Wainwright & Co. Global Life Sciences Conference. Leen Kawas, Ph.D., President and CEO, will lead the pre-recorded presentation available at 7:00 am ET on March 9, 2021. The presentation can be accessed on-demand through the Athira website, with an archived replay available for 90 days post-event. Athira focuses on developing small molecules to restore neuronal health, targeting Alzheimer’s and Parkinson’s dementia with its lead candidate, ATH-1017.
Athira Pharma, Inc. (Nasdaq: ATHA) announced that underwriters exercised their option to purchase an additional 600,000 shares at $22.50 each, generating total gross proceeds of $103.5 million from its public offering. The closing of this sale occurred on February 10, 2021. Goldman Sachs, Jefferies, and Stifel managed the offering, which became effective after a registration statement filed with the SEC on January 20, 2021. The offering is strictly subject to the terms outlined in the prospectus and does not constitute an offer to sell securities in jurisdictions where it would be unlawful.
Athira Pharma has announced a public offering of 4,000,000 shares of common stock at a price of $22.50 per share, aiming to raise gross proceeds of $90 million. The offering is expected to close on January 25, 2021, pending standard closing conditions. Athira has also granted underwriters a 30-day option to purchase an additional 600,000 shares. The offering is being managed by Goldman Sachs, Jefferies, and Stifel, with a registration statement that became effective on January 20, 2021. The proceeds will support the company’s efforts in developing therapies for neurodegeneration.
Athira Pharma has launched an underwritten public offering of 4,000,000 shares of its common stock, with an additional option for underwriters to purchase 600,000 more shares. The offering will be conducted by Goldman Sachs, Jefferies, and Stifel as joint book-running managers. The offering is subject to market conditions and the registration statement is pending effectiveness. This move aims to raise capital for ongoing development efforts in restoring neuronal health and combating neurodegeneration. Further details are accessible via the underwriters.
Athira Pharma, a late clinical-stage biopharmaceutical company listed on NASDAQ under the symbol ATHA, announced that its President and CEO, Leen Kawas, Ph.D., will present at the 39th Annual J.P. Morgan Conference on January 14, 2021, at 2:50 p.m. ET. The presentation will focus on the company's pipeline and innovations aimed at restoring neuronal health and combating neurodegeneration.
A live webcast will be available on the company's investor website, with an archived replay accessible for 90 days post-presentation.
Athira Pharma (NASDAQ: ATHA) announced the appointment of Kelly A. Romano to its Board of Directors. Romano, founder of BlueRipple Capital, brings over 30 years of experience in technology and operations, previously serving at United Technologies Corp. Her addition aims to support Athira's goal of advancing ATH-1017 for Alzheimer’s disease in clinical trials. Athira’s efforts focus on developing treatments that restore neuronal health, with promising clinical data for ATH-1017 noted. The company emphasizes ongoing commitment to patient care in neurodegenerative diseases.
Athira Pharma (NASDAQ: ATHA) has received a $15 million research grant from the National Institute on Aging to support the ACT-AD Phase 2 clinical trial for its lead candidate, ATH-1017, targeting mild-to-moderate Alzheimer's disease. This grant emphasizes the federal commitment to advancing innovative research in cognitive health. The ACT-AD trial will assess ATH-1017's impact on cognitive functions using quantitative EEG and other metrics. ATH-1017 aims to enhance brain health by targeting Hepatocyte Growth Factor and its receptor, MET.
Athira Pharma (NASDAQ: ATHA) has initiated patient dosing in the Phase 2 ACT-AD clinical trial, focusing on its drug ATH-1017 for mild-to-moderate Alzheimer’s disease. This randomized, placebo-controlled study will enroll around 75 participants across the US and Australia, evaluating cognitive improvements over 26 weeks. The trial aims to use EEG measures to assess brain function, building on previous data from the LIFT-AD trial. Athira aims to leverage this innovative approach to advance their treatment options for Alzheimer’s and potentially other dementias.
Athira Pharma (NASDAQ: ATHA) announced significant developments in their LIFT-AD clinical trial for ATH-1017, focusing on mild-to-moderate Alzheimer’s disease. The trial is actively enrolling patients, and dosing has commenced. As of September 30, 2020, the company reported a robust cash position of $259.9 million, a notable increase from $85.2 million in June 2020. R&D expenses rose to $5.8 million due to clinical trial preparations, while G&A expenses increased to $1.6 million. The net loss for Q3 2020 was $8.5 million, or $1.12 per share.
Athira Pharma (NASDAQ: ATHA), a clinical-stage biopharmaceutical company, announced participation by Dr. Leen Kawas and Dr. Hans Moebius in upcoming investor conferences. They will present at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, and at the Jefferies Virtual London Healthcare Conference on November 19, 2020. Live webcasts of both events will be available through the Athira website, with archived replays accessible for 90 days after the presentations. Athira focuses on developing small molecules aimed at restoring neuronal health and treating neurodegenerative diseases.
FAQ
What is the current stock price of Athira Pharma (ATHA)?
What is the market cap of Athira Pharma (ATHA)?
